Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandospirone for Anxiety in Alzheimer's Disease
NCT03151382Phase 4Unknown
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- May 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of tandospirone in Alzheimer's disease (AD) (2 arms), sponsored by Zhejiang Provincial People's Hospital. Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 12 weeks and Neuropsychiatric Inventory at 12 weeks. Status: unknown.
02
Drugs
tandospirone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03151382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151382.